These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 19318138)
1. A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction. Blasey CM; Debattista C; Roe R; Block T; Belanoff JK Contemp Clin Trials; 2009 Jul; 30(4):284-8. PubMed ID: 19318138 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of mifepristone for the treatment of psychotic depression. Blasey CM; Block TS; Belanoff JK; Roe RL J Clin Psychopharmacol; 2011 Aug; 31(4):436-40. PubMed ID: 21694614 [TBL] [Abstract][Full Text] [Related]
3. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. DeBattista C; Belanoff J; Glass S; Khan A; Horne RL; Blasey C; Carpenter LL; Alva G Biol Psychiatry; 2006 Dec; 60(12):1343-9. PubMed ID: 16889757 [TBL] [Abstract][Full Text] [Related]
4. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. Block T; Petrides G; Kushner H; Kalin N; Belanoff J; Schatzberg A J Clin Psychopharmacol; 2017 Oct; 37(5):505-511. PubMed ID: 28708736 [TBL] [Abstract][Full Text] [Related]
5. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115 [TBL] [Abstract][Full Text] [Related]
6. Clinical and biological effects of mifepristone treatment for psychotic depression. Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710 [TBL] [Abstract][Full Text] [Related]
7. Risperidone in the treatment of psychotic depression. Goto M; Yoshimura R; Kakihara S; Shinkai K; Yamada Y; Kaji K; Ueda N; Nakamura J Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):701-7. PubMed ID: 16580110 [TBL] [Abstract][Full Text] [Related]
8. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874 [TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
10. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial]. Shiloh R; Weizman A; Weizer N; Dorfman-Etrog P; Munitz H Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053 [TBL] [Abstract][Full Text] [Related]
11. Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Nihalani ND; Schwartz TL Curr Opin Investig Drugs; 2007 Jul; 8(7):563-9. PubMed ID: 17659476 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825 [TBL] [Abstract][Full Text] [Related]
13. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Block TS; Kushner H; Kalin N; Nelson C; Belanoff J; Schatzberg A Biol Psychiatry; 2018 Jul; 84(1):46-54. PubMed ID: 29523415 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of imipramine in psychotic versus nonpsychotic depression. Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726 [TBL] [Abstract][Full Text] [Related]
16. Inositol augmentation of lithium or valproate for bipolar depression. Eden Evins A; Demopulos C; Yovel I; Culhane M; Ogutha J; Grandin LD; Nierenberg AA; Sachs GS Bipolar Disord; 2006 Apr; 8(2):168-74. PubMed ID: 16542187 [TBL] [Abstract][Full Text] [Related]
17. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia. Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098 [TBL] [Abstract][Full Text] [Related]
18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE; Franznick DA; Hollander SB; Fava M J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [TBL] [Abstract][Full Text] [Related]
19. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. Simpson GM; El Sheshai A; Loza N; Kingsbury SJ; Fayek M; Rady A; Fawzy W J Clin Psychiatry; 2005 May; 66(5):598-602. PubMed ID: 15889946 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. Politis AM; Papadimitriou GN; Theleritis CG; Psarros C; Soldatos CR Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1227-30. PubMed ID: 18442877 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]